acorda

Josh SandbergMarch 22, 2010
616

Acorda Therapeutics Announces Filing of Patent Extension Applications for AMPYRA(TM) (dalfampridine)

HAWTHORNE, N.Y., Mar 22, 2010 (BUSINESS WIRE) — Acorda Therapeutics, Inc. (ACOR 34.95, +0.11, +0.32%)today announced that the Company has submitted applications to…
Read More »
Josh SandbergFebruary 22, 2010
587

Acorda Therapeutics Announces Adrian L. Rabinowicz Joins as Senior Vice President of Medical Affairs

HAWTHORNE, N.Y., Feb 22, 2010 (BUSINESS WIRE) — Acorda Therapeutics, Inc. (ACOR 31.71, -0.23, -0.72%)announced today that Adrian L. Rabinowicz, M.D., FAAN, has…
Read More »
Josh SandbergJanuary 25, 2010
941

Acorda Therapeutics Announces Lauren Sabella Joins as Executive Vice President of Commercial Development

HAWTHORNE, N.Y.–(BUSINESS WIRE)–Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced today that Lauren Sabella has joined the Company as Executive Vice President,…
Read More »
Josh SandbergJanuary 4, 2010
556

Acorda Therapeutics to Present at the 28th Annual JPMorgan Healthcare Conference

HAWTHORNE, N.Y.–(BUSINESS WIRE)–Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Ron Cohen, M.D., President & CEO, will present at the…
Read More »